Unknown

Dataset Information

0

Ruthenium Complex HB324 Induces Apoptosis via Mitochondrial Pathway with an Upregulation of Harakiri and Overcomes Cisplatin Resistance in Neuroblastoma Cells In Vitro.

ABSTRACT: Ruthenium(II) complexes with N-heterocyclic carbene (NHC) ligands have recently attracted attention as novel chemotherapeutic agents. The complex HB324 was intensively studied as an apoptosis-inducing compound in resistant cell lines. HB324 induced apoptosis via mitochondrial pathways. Of particular interest is the upregulation of the Harakiri resistance protein, which inhibits the anti-apoptotic and death repressor proteins Bcl-2 (B-cell lymphoma 2) and BCL-xL (B-cell lymphoma-extra large). Moreover, HB324 showed synergistic activity with various established anticancer drugs and overcame resistance in several cell lines, such as neuroblastoma cells. In conclusion, HB324 showed promising potential as a novel anticancer agent in vitro, suggesting further investigations on this and other preclinical ruthenium drug candidates.

SUBMITTER: Wilke NL 

PROVIDER: S-EPMC9866957 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Ruthenium Complex HB324 Induces Apoptosis via Mitochondrial Pathway with an Upregulation of Harakiri and Overcomes Cisplatin Resistance in Neuroblastoma Cells In Vitro.

Wilke Nicola L NL   Burmeister Hilke H   Frias Corazon C   Ott Ingo I   Prokop Aram A  

International journal of molecular sciences 20230104 2

Ruthenium(II) complexes with N-heterocyclic carbene (NHC) ligands have recently attracted attention as novel chemotherapeutic agents. The complex HB324 was intensively studied as an apoptosis-inducing compound in resistant cell lines. HB324 induced apoptosis via mitochondrial pathways. Of particular interest is the upregulation of the Harakiri resistance protein, which inhibits the anti-apoptotic and death repressor proteins Bcl-2 (B-cell lymphoma 2) and BCL-xL (B-cell lymphoma-extra large). Mor  ...[more]

Similar Datasets

Unknown KP772 overcomes multiple drug resistance in malignant lymphoma and leukemia cells in vitro by inducing Bcl-2-independent apoptosis and upregulation of Harakiri.
| S-EPMC8557194 | biostudies-literature
Unknown Nifurtimox induces apoptosis of neuroblastoma cells in vitro and in vivo.
| S-EPMC4445366 | biostudies-literature
Unknown Ellagic Acid Induces DNA Damage and Apoptosis in Cancer Stem-like Cells and Overcomes Cisplatin Resistance.
| S-EPMC11656259 | biostudies-literature
Unknown Simvastatin Induces Delayed Apoptosis Through Disruption of Glycolysis and Mitochondrial Impairment in Neuroblastoma Cells.
| S-EPMC7214657 | biostudies-literature
Unknown Upregulation of LYAR induces neuroblastoma cell proliferation and survival.
| S-EPMC5563997 | biostudies-literature
Unknown cAMP induces cell apoptosis in multiple myeloma and overcomes bortezomib resistance.
| S-EPMC5794718 | biostudies-literature
Unknown Cisplatin Induces Apoptosis in Mouse Neonatal Testes Organ Culture.
| S-EPMC9658841 | biostudies-literature
Unknown Dihydroxyquingdainone Induces Apoptosis in Leukaemia and Lymphoma Cells via the Mitochondrial Pathway in a Bcl-2- and Caspase-3-Dependent Manner and Overcomes Resistance to Cytostatic Drugs In Vitro.
| S-EPMC9370279 | biostudies-literature
Unknown FTY-720 induces apoptosis in neuroblastoma via multiple signaling pathways.
| S-EPMC5746359 | biostudies-literature
Unknown Cisplatin induces mitochondrial deficits in Drosophila larval segmental nerve.
| S-EPMC5138083 | biostudies-literature